… Philadelphia (Ph) … IFN (recombinant IFN alpha or pegylated IFN alpha-2a) achieved stable
MRs and was associated with high rates of treatment discontinuation in a cohort of 20 chronic …

… had addition of unidentified chromosomal material in Ph-negative metaphases. Mutation …
Combination of dasatinib and Peg-interferon alpha 2b in chronic phase chronic myeloid …

… CCyR was defined as the absence of Ph + metaphases. In … Imatinib discontinuation in
chronic phase myeloid leukaemia patients in sustained complete molecular response: a …

… Chronic inflammation and a dysregulated immune system … Interferon alpha (IFNα) was first
used for the treatment of MPNs … role of IFNα in the treatment of Ph-negative MPNs through a …

… -positive chronic myeloid leukemia (CML) have been described so far. Here we report the
case of a patient … , treated with imatinib and pegylated interferon (IFN) frontline. She reached …

… The translocation t(9; 22), also known as “Philadelphia chromosome” (Ph), leads … chronic
myelogenous leukemia. MPN without this mutation are classified as Philadelphia-negative (Ph …

… Dasatinib in the treatment of chronic myeloid leukemia in … effective in patients with chronic
myeloid leukemia in chronic phase … to interferon-alphabased therapy for chronic myelogenous …

… /day as front-line therapy in chronic phase-chronic myeloid leukaemia (CP-CML) patients.
When … Higher risk scores and more Ph + additional cytogenetic abnormalities (ACAs) 16 were …

… therapy of BCR-ABL-positive leukemias, either used as single agent in chronic myeloid
leukemia (… chemotherapy in Philadelphia-positive (Ph + ) acute lymphoblastic leukemia (ALL). …

… aim of this study was to evaluate the role of IFN a-2b in the treatment of Ph’ negative CMD
… shows that IFN r-2b at relatively low doses has definite therapeutic activity in patients with …